Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Company News

Novo gets option to cardiovascular company Staten

Alicia Parker
December 17, 2018 11:26 PM UTC

Novo Nordisk A/S (CSE:NOVO B; NYSE:NVO) received an option to acquire Staten Biotechnology B.V. (Nijmegen, the Netherlands) along with its lead candidate, STT-5058, which is in development to reduce cardiovascular risk in patients with hypertriglyceridemia.

Staten will conduct a Phase I trial of the antibody against apolipoprotein C-III (APOCIII; APOC3) in the next two years, after which Novo can acquire the company for an €100 million ($113.2 million) option exercise fee and up to €300 million ($340 million) in milestones...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

Novo Nordisk A/S

Staten Biotechnology B.V.